**Abstract**

**Aims:** Several in vitro studies have suggested that escitalopram is a substrate of CYP2C19. In addition, plasma concentrations of S-enantiomer of citalopram were different between extensive metabolizers and poor metabolizers of CYP2C19 in healthy subjects and depressed patients. Thus, we studied the effects of polymorphisms of CYP2C19 gene on plasma drug concentrations in Japanese depressed patients.

**Methods:** Subjects were 412 depressed patients receiving 5, 10, 15 and 20 mg once a day of escitalopram. The mean ± SD (range) of age and body weight were 43.1±17.3 (19--80) years, and 60.3±13.4 (34--91) kg, respectively. Sample collections were conducted 14--16 h after the bedtime dosing. Plasma concentrations of escitalopram and desmethylescitalopram were quantitated using HPLC. CYP2C19 genotypes were identified using PCR methods. The study was approved by the Ethics Committee of Hirosaki University Hospital, and written informed consent to participate in this study was obtained from the patients.

**Results:** There was no difference in steady-state plasma concentrations of escitalopram in 5, 10, 15 or 20 mg of escitalopram. However, ANOVA showed a significant difference in dose-adjusted plasma concentration of escitalopram but not in dose adjusted plasma concentration of desmethylescitalopram. ANCOVA including age, sex and body weight showed significant differences in dose-adjusted plasma concentration of escitalopram and in ratio of desmethylescitalopram and escitalopram.

**Conclusion:** These findings suggest that the CYP2C19 variants are associated with steady-state plasma concentration of escitalopram but not with desmethylescitalopram.
